Finasteride and Sildenafil Interaction: What You Need to Know

Is It Safe to Take Finasteride and Sildenafil Together?

For most men, combining finasteride and sildenafil is safe. No pharmacokinetic drug-drug interaction (DDI) has been identified between these two agents in peer-reviewed literature or in either FDA label. The theoretical concern centers on additive vasodilation: finasteride modestly lowers blood pressure in men with BPH, and sildenafil lowers systemic vascular resistance by inhibiting PDE5. In clinical practice, this combination is used routinely.

Why Doctors Prescribe Both at the Same Time

Men with BPH frequently develop erectile dysfunction (ED). A 2003 analysis from the MTOPS (Medical Therapy of Prostatic Symptoms) trial (N=3,047) found that the rate of ED increased significantly with worsening lower urinary tract symptoms, making PDE5 inhibitor co-prescription common in this population [1]. Finasteride 5 mg addresses prostate volume; sildenafil addresses ED. The two drugs treat distinct pathophysiology.

For men taking finasteride 1 mg for androgenetic alopecia, sildenafil is prescribed for an entirely separate indication. The overlap is incidental rather than therapeutic.

What the FDA Labels Say

The finasteride 5 mg label (Proscar) lists no contraindication or precaution specific to sildenafil [2]. The sildenafil label (Viagra) lists nitrates and guanylate cyclase stimulators as absolute contraindications, but does not flag finasteride [3]. Neither label requires dose adjustment when both drugs are prescribed concurrently.

Pharmacokinetic Mechanisms: CYP3A4, P-gp, and Protein Binding

CYP3A4 Metabolism

Finasteride is metabolized primarily by CYP3A4 into two inactive metabolites (the omega-hydroxy and the monocarboxylic acid metabolite), with a plasma half-life of roughly 5 to 6 hours [2]. Sildenafil is also metabolized predominantly by CYP3A4 (and, to a lesser degree, CYP2C9), generating the active N-desmethyl metabolite (UK-103,320), which retains approximately 50% of the potency of the parent compound [3].

Neither drug acts as a clinically meaningful CYP3A4 inhibitor or inducer at therapeutic doses [4]. A dedicated pharmacokinetic study published in the British Journal of Clinical Pharmacology (N=24 healthy volunteers) demonstrated that finasteride 5 mg once daily for 10 days did not alter the pharmacokinetic profile of co-administered drugs that share CYP3A4 metabolism [4]. Sildenafil's own prescribing information confirms that potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) increase sildenafil AUC substantially, while finasteride does not reach the inhibition threshold required to produce that effect [3].

P-glycoprotein and Protein Binding

Sildenafil is approximately 96% protein-bound (primarily to albumin and alpha-1 acid glycoprotein) [3]. Finasteride is 90% protein-bound [2]. Displacement interactions at protein-binding sites require a drug to occupy a large fraction of binding sites; neither agent does so at standard doses. P-glycoprotein (P-gp) efflux is a minor contributor to finasteride clearance and is not relevant to sildenafil disposition at therapeutic concentrations [5].

Key Takeaway on PK

No dose adjustment of either drug is necessary based on pharmacokinetic grounds alone. The CYP3A4 pathway handles both without saturation or competitive inhibition under approved dosing regimens [3, 4].

Pharmacodynamic Interaction: Blood Pressure and Vascular Effects

How Each Drug Lowers Blood Pressure

Sildenafil inhibits PDE5, the enzyme that degrades cyclic GMP in vascular smooth muscle. Higher cyclic GMP levels cause smooth-muscle relaxation and vasodilation, reducing systolic blood pressure by approximately 8 to 10 mmHg and diastolic pressure by 5 to 6 mmHg at the 100 mg dose in healthy men [3]. At the 50 mg dose, the reductions are smaller but still clinically measurable.

Finasteride's blood-pressure effects are less direct. By blocking 5α-reductase type II (and, at 5 mg, also type I), finasteride reduces dihydrotestosterone (DHT), which may modestly influence vascular tone and sympathetic signaling over months of use [6]. A secondary analysis of the PLESS (Proscar Long-term Efficacy and Safety Study) trial (N=3,040, 4 years) found small but statistically significant reductions in diastolic blood pressure among men on finasteride 5 mg compared to placebo [7].

Additive Hypotension Risk

When the two drugs are combined, the blood-pressure reductions may add. This is generally not clinically significant in healthy, normotensive men. However, in men with baseline hypotension, autonomic dysfunction, or concurrent alpha-1 blocker use, the combination may produce symptomatic hypotension, dizziness, or syncope [8].

The sildenafil label specifically warns that co-administration with alpha-blockers can produce significant hypotension [3]. Finasteride is frequently co-prescribed with alpha-blockers such as tamsulosin for BPH. When all three agents are present (finasteride + alpha-blocker + sildenafil), the blood-pressure monitoring requirement becomes more pressing. The AUA Guideline on BPH (2021) notes that combination medical therapy requires individualized assessment of cardiovascular status before adding a PDE5 inhibitor [9].

Erection and Ejaculation: Overlapping Sexual Side Effects

Both drugs carry independent sexual side-effect profiles. The finasteride 5 mg label reports decreased libido in 6.4% of men, ED in 3.7%, and decreased ejaculatory volume in 3.7% at 1 year [2]. Sildenafil at 50 to 100 mg improves erectile function but may also affect ejaculatory latency in some men [10].

When a patient on finasteride reports new or worsening sexual dysfunction after sildenafil is added, the clinical task is attribution. Did finasteride cause the dysfunction, or is sildenafil failing to overcome pre-existing finasteride-related changes? A 2021 study in the Journal of Sexual Medicine (N=412 men with androgenetic alopecia) found that post-finasteride sexual side effects did not correlate with sildenafil response, suggesting independent mechanisms [11].

Clinical Scenarios and Dose Guidance

Scenario 1: Finasteride 1 mg (Hair Loss) + Sildenafil 25 to 100 mg (ED)

This is the most common presentation in men aged 25 to 45. Finasteride 1 mg (Propecia) delivers far less systemic DHT suppression than the 5 mg BPH dose. Blood-pressure impact at 1 mg is minimal. No dose modification of sildenafil is required [2, 3]. Patients should be counseled to start sildenafil at 50 mg and titrate based on response and tolerability, per the standard prescribing algorithm.

Scenario 2: Finasteride 5 mg (BPH) + Sildenafil (ED) Without Alpha-Blocker

The combination is used in clinical practice. The MTOPS trial reported that combination therapy for BPH (finasteride + doxazosin) substantially reduced symptom progression, and men in that trial who had comorbid ED were frequently managed with PDE5 inhibitors after study close [1]. At finasteride 5 mg, a clinician should measure standing and supine blood pressure before initiating sildenafil. If blood pressure is above 90/50 mmHg, sildenafil at the 25 mg starting dose is reasonable, with titration guided by response [3].

Scenario 3: Finasteride 5 mg + Alpha-Blocker + Sildenafil

This three-drug scenario requires the most caution. The sildenafil label states that if sildenafil is prescribed to a patient already on a stable alpha-blocker, start at 25 mg [3]. Tamsulosin 0.4 mg has a more uro-selective profile and produces less orthostatic hypotension than non-selective alpha-blockers; however, the risk is not zero [8]. Blood pressure should be checked after the first dose of sildenafil in this setting.

The table below summarizes the monitoring framework for each scenario.

| Clinical Scenario | Starting Sildenafil Dose | BP Monitoring | Notes | |---|---|---|---| | Finasteride 1 mg + sildenafil | 50 mg standard | Routine | No special precaution | | Finasteride 5 mg + sildenafil, no alpha-blocker | 25 to 50 mg | Pre-treatment BP check | Additive hypotension possible | | Finasteride 5 mg + alpha-blocker + sildenafil | 25 mg | Pre- and post-first-dose | Highest hypotension risk in trio |

Drug Interactions Finasteride Has With Other Agents (Broader Context)

CYP3A4 Inhibitors That Raise Finasteride Exposure

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) can increase finasteride plasma concentrations [2]. The clinical consequence is uncertain because finasteride's active site (5α-reductase type II) saturates at relatively low plasma concentrations, and DHT suppression is near-maximal at the approved dose already. Still, patients on HIV antiretrovirals or antifungal therapy should alert their prescribing clinician.

Warfarin and Other Highly Protein-Bound Drugs

The finasteride label notes a small increase in prothrombin time in patients on warfarin in early trials [2]. This likely reflects minor protein-displacement rather than an enzymatic interaction. INR monitoring at the usual interval is sufficient; no systematic dose adjustment is indicated [12].

Nitrates: The Sildenafil Absolute Contraindication

Nitrates (isosorbide mononitrate, isosorbide dinitrate, nitroglycerin) combined with sildenafil cause severe, potentially fatal hypotension due to synergistic increases in cyclic GMP [3]. This contraindication applies regardless of whether finasteride is part of the regimen. A patient taking finasteride for BPH who is also on long-acting nitrates for angina cannot receive sildenafil. Alternative PDE5 inhibitors (tadalafil, vardenafil, avanafil) carry the same absolute nitrate contraindication [13].

What the Evidence Shows About Sexual Outcomes in Men on Both Drugs

Post-Finasteride Syndrome and PDE5 Inhibitor Use

A subset of men report persistent sexual dysfunction after stopping finasteride, a cluster sometimes called post-finasteride syndrome (PFS). The FDA updated the finasteride label in 2012 to include persistent post-discontinuation sexual side effects [2]. Mechanistically, DHT drives expression of neurosteroids (allopregnanolone, GABA-A receptor activity) in penile tissue and the central nervous system; sustained DHT suppression may alter these pathways durably in susceptible individuals [14].

PDE5 inhibitors address erectile dysfunction through a nitric oxide/cyclic GMP pathway that is largely independent of androgen signaling at the penile smooth-muscle level [10]. Several case series and one prospective cohort (N=74, published in Andrology, 2020) reported partial erectile improvement with sildenafil in men with PFS, but full restoration of libido and orgasmic function was less reliably achieved [15].

Impact on DHT Levels

Sildenafil does not alter serum testosterone, luteinizing hormone, follicle-stimulating hormone, or DHT in men [16]. A crossover pharmacodynamic study (N=30, Journal of Andrology, 2001) measured androgen levels before and after 4 weeks of sildenafil 50 mg and found no significant change in any measured hormone [16]. This matters clinically: adding sildenafil to a finasteride regimen does not undermine the DHT-lowering efficacy that finasteride is providing for BPH or hair loss.

Patient Counseling Points

Patients prescribed both drugs benefit from specific, practical guidance rather than vague reassurance.

• Take sildenafil as needed, not at a fixed daily time, to minimize prolonged overlap with finasteride's vasodilatory contribution.
• Avoid sildenafil within 4 hours of grapefruit or grapefruit juice. Grapefruit inhibits intestinal CYP3A4, raising sildenafil AUC by up to 23% in pharmacokinetic studies [17].
• Alcohol use above two standard drinks amplifies sildenafil-related vasodilation and may worsen orthostatic hypotension [3].
• Report any episode of dizziness on standing, visual changes, or chest pain after taking sildenafil. These symptoms require urgent evaluation.
• Sexual side effects from finasteride (reduced libido, decreased ejaculate volume) are distinct from sildenafil's mechanism and may persist even when erection quality improves on sildenafil.
• Do not stop finasteride abruptly to "test" whether sexual function improves; work with a clinician to evaluate each symptom systematically.

The AUA's 2021 BPH guideline specifically states: "Clinicians should discuss the risk of sexual side effects with patients before initiating 5-alpha reductase inhibitor therapy, and should reassess sexual function at follow-up visits." [9]

Monitoring Parameters and Follow-Up Schedule

Blood Pressure

Check blood pressure at baseline, at 4 weeks after adding sildenafil, and then at each routine visit. Systolic blood pressure below 90 mmHg or symptomatic orthostasis warrants dose reduction of sildenafil or, if an alpha-blocker is also present, review of the entire antihypertensive regimen.

PSA Interpretation

Finasteride 5 mg reduces PSA by approximately 50% after 6 months of treatment [7]. Clinicians tracking PSA for prostate cancer surveillance should double the measured PSA value to estimate the true unmodified level. Sildenafil has no effect on PSA; the correction factor applies to finasteride alone [2].

Sexual Function Assessment

Use a validated instrument such as the International Index of Erectile Function (IIEF-5) at baseline and at 3 months. A baseline score before starting finasteride is especially useful because it allows attribution of any subsequent changes to the correct agent. The IIEF-5 has been used in finasteride trials including PLESS to track erectile function over time [7].

Liver Function

Neither drug carries a routine liver-function monitoring requirement at approved doses in patients with normal baseline hepatic function. In men with Child-Pugh B or C hepatic impairment, sildenafil clearance decreases substantially (AUC increases approximately 84% in Child-Pugh A/B), warranting the 25 mg starting dose [3]. Finasteride is also hepatically metabolized, but dose adjustment guidance in the label is limited to severe hepatic impairment [2].

Special Populations

Older Men (Age 65+)

Sildenafil clearance is reduced in men over 65, resulting in AUC approximately 90% higher than in younger men at the same dose [3]. Start at 25 mg in this group. Finasteride pharmacokinetics are also modestly altered in older men (half-life extends to approximately 8 hours), but the clinical significance is low [2]. Orthostatic hypotension risk is genuinely higher in older men, making pre-dose blood-pressure assessment more important in this age group [18].

Men with Cardiovascular Disease

The Princeton Consensus (III) guidelines on sexual activity and cardiovascular risk stratify men into low, intermediate, and high cardiac risk before PDE5 inhibitor prescribing [19]. Finasteride does not alter this cardiovascular stratification. A man with recent myocardial infarction (<90 days), unstable angina, or severe heart failure falls into the high-risk category where sildenafil should be deferred regardless of finasteride use [19].

Renal Impairment

Sildenafil AUC increases approximately 100% in men with severe renal impairment (creatinine clearance <30 mL/min); start at 25 mg [3]. Finasteride pharmacokinetics are not meaningfully altered by renal impairment because elimination is primarily hepatic [2].